Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Illumina    ILMN

ILLUMINA (ILMN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Illumina : BlueMountain Capital Management LLC Acquires New Position in Illumina, Inc

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/21/2017 | 12:26pm CEST

BlueMountain Capital Management LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 9,414 shares of the life sciences companys stock, valued at approximately $1,634,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. First Citizens Bank & Trust Co. boosted its stake in shares of Illumina by 0.4% during the second quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences companys stock valued at $536,000 after acquiring an additional 12 shares during the last quarter. Patten Group Inc. boosted its stake in shares of Illumina by 2.7% during the first quarter. Patten Group Inc. now owns 965 shares of the life sciences companys stock valued at $166,000 after acquiring an additional 25 shares during the last quarter. Puzo Michael J boosted its stake in shares of Illumina by 0.4% during the second quarter. Puzo Michael J now owns 5,955 shares of the life sciences companys stock valued at $1,032,000 after acquiring an additional 25 shares during the last quarter. Flagship Harbor Advisors LLC boosted its stake in shares of Illumina by 1.7% during the second quarter. Flagship Harbor Advisors LLC now owns 2,046 shares of the life sciences companys stock valued at $345,000 after acquiring an additional 35 shares during the last quarter. Finally, Eqis Capital Management Inc. boosted its stake in shares of Illumina by 0.6% during the second quarter. Eqis Capital Management Inc. now owns 6,914 shares of the life sciences companys stock valued at $1,200,000 after acquiring an additional 38 shares during the last quarter. 93.32% of the stock is currently owned by institutional investors and hedge funds.

Illumina, Inc. (NASDAQ ILMN) opened at 209.40 on Tuesday. The stock has a 50 day moving average price of $198.87 and a 200-day moving average price of $180.90. The stock has a market capitalization of $30.57 billion, a P/E ratio of 42.01 and a beta of 0.81. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $214.34.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating analysts consensus estimates of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm had revenue of $662.00 million for the quarter, compared to the consensus estimate of $642.38 million. During the same quarter in the previous year, the company posted $0.86 earnings per share. The businesss quarterly revenue was up 10.3% compared to the same quarter last year. Equities research analysts expect that Illumina, Inc. will post $3.65 EPS for the current year.

A number of research firms recently commented on ILMN. Argus increased their price objective on Illumina from $205.00 to $235.00 and gave the company a buy rating in a research note on Wednesday, September 13th. Leerink Swann reaffirmed an outperform rating and set a $225.00 price objective (up previously from $207.00) on shares of Illumina in a research note on Tuesday, September 12th. Vetr lowered Illumina from a buy rating to a hold rating and set a $209.78 price objective on the stock. in a research note on Thursday, August 31st. Zacks Investment Research lowered Illumina from a buy rating to a hold rating in a research note on Friday, August 4th. Finally, Barclays PLC reaffirmed an equal weight rating and set a $150.00 price objective on shares of Illumina in a research note on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the stock. Illumina currently has an average rating of Hold and a consensus price target of $181.76.

In other Illumina news, Director Jay T. Flatley sold 15,000 shares of the businesss stock in a transaction dated Tuesday, July 18th. The stock was sold at an average price of $170.77, for a total value of $2,561,550.00. Following the transaction, the director now owns 534,176 shares in the company, valued at $91,221,235.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Oene Mark Van sold 9,729 shares of the companys stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $211.33, for a total value of $2,056,029.57. Following the sale, the senior vice president now owns 24,908 shares of the companys stock, valued at approximately $5,263,807.64. The disclosure for this sale can be found here. Insiders sold 195,434 shares of company stock worth $37,480,647 in the last 90 days. Corporate insiders own 1.60% of the companys stock.

(c) 2017 Al Hilal Publishing and Marketing Group Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ILLUMINA
09/21 ILLUMINA : BlueMountain Capital Management LLC Acquires New Position in Illumina..
09/19 ILLUMINA : $52,289 Federal Contract Awarded to Illumina
09/07 ILLUMINA : Patent Issued for Compositions and Methods for Preparing Oligonucleot..
09/07 ILLUMINA : Files New Patent Infringement Suit Against Premaitha Health plc
09/01 ILLUMINA : Special Notice - 66-- Project Legacy Illumina Reagents PLMS
08/30 PRESOLICITATION NOTICE - TITLE : Notice of Intent to Sole Source - Tru Seq Methy..
08/26 ILLUMINA : Federal Contracts Awarded by Federal Agencies in Maryland (Aug. 26)
08/26 ILLUMINA : MILITARY $429,892 Federal Contract Awarded to Illumina
08/24 ILLUMINA : Presolicitation Notice - Illumina Reagents
08/24 ILLUMINA : Presolicitation Notice - Notice of Intent to Soule Source for Illumin..
More news
News from SeekingAlpha
08/18 Illumina, Inc. 2017 Q2 - Results - Earnings Call Slides
08/12 Best And Worst Performing S&P 500 Stocks On Earnings
08/10 Viral Success For Grail But Not With Core Tech
08/09 ProLung Files For $8 Million Mini-IPO
08/09 VALUATION DASHBOARD : Healthcare - Update
Financials ($)
Sales 2017 2 683 M
EBIT 2017 645 M
Net income 2017 792 M
Finance 2017 828 M
Yield 2017 -
P/E ratio 2017 37,18
P/E ratio 2018 49,15
EV / Sales 2017 10,6x
EV / Sales 2018 9,18x
Capitalization 29 295 M
Chart ILLUMINA
Duration : Period :
Illumina Technical Analysis Chart | ILMN | US4523271090 | 4-Traders
Technical analysis trends ILLUMINA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 186 $
Spread / Average Target -7,0%
EPS Revisions
Managers
NameTitle
Francis A. deSouza President, Chief Executive Officer & Director
Jay T. Flatley Executive Chairman
Ostadan Omead Executive VP-Operations, Products & Strategy
Sam A. Samad Chief Financial Officer & Senior Vice President
Mostafa Ronaghi Chief Technology Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ILLUMINA58.61%29 295
THERMO FISHER SCIENTIFIC INC.33.18%74 956
DANAHER11.02%60 035
ROYAL PHILIPS21.62%39 695
BOSTON SCIENTIFIC CORPORATION33.33%39 462
INTUITIVE SURGICAL62.45%38 273